Michael J. Akers, PhD - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

KeywordLocation
About Search
Michael J. Akers, PhD


Michael J. Akers Pharmtech editorial advisory board (EAB) member

Michael J. Akers, PhD
Senior Director,
Pharmaceutical R&D,
Baxter BioPharma Solutions

Micheal J. Akers is senior director of pharmaceutical research and development at Baxter BioPharma Solutions in Bloomington, Indiana. He leads the Baxter Center of Lyophilization Excellence. Akers is active in the AAPS and PDA organizations, where in the past he has served on their leadership boards as well as being a Fellow of the American Association of Pharmaceutical Scientists (AAPS). He also serves on the United States Pharmacopeia Parenteral Products Expert Committee.

Akers is editor-in-chief of Pharmaceutical Development and Technology. He has published more than 100 research articles, teaching articles, review articles and book chapters, including the Parenterals chapter for the 21st edition of Remington’s: The Science and Practice of Pharmacy. He has also authored/edited four books. He teaches several continuing education courses each year on the basics of sterile product science and technology. Akers received his PhD degree in Pharmaceutics from the University of Iowa College of Pharmacy.

ADVERTISEMENT

post a comment
Your email address will NOT be published.
appears with your comment
read our privacy policy
Note: does not support HTML
All comments submitted are subject to review, and may be delayed before posting. We reserve the right not to post comments.
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What factor do you think will be most significant in 2010 for determining the health of the market for contract manufacturing of active pharmaceutical ingredients?
The global economic recovery
The US economic recovery
Improved credit and financing flow to the small to emerging pharma/bio sector
Less restrictive inventory control by pharmaceutical companies
The level of competition from contract manufacturers in emerging markets
The global economic recovery
39%
The US economic recovery
14%
Improved credit and financing flow to the small to emerging pharma/bio sector
15%
Less restrictive inventory control by pharmaceutical companies
8%
The level of competition from contract manufacturers in emerging markets
24%
View Results
Eric LangerOutsourcing OutlookEric Langer A Bio View of Outsourcing
Patricia Van ArnumIngredients InsiderPatricia Van Arnum Advances in Custom Synthesis
Faiz kermaniSpotlightFaiz Kermani EU pricing dilemmas
Faiz kermaniStatistical Solutions Lynn Torbeck%RSD: Friend or Foe?
NSF, Microsoft Team in Cloud Computing
Keep an eye on that cargo
Pharma packs a punch
Another Boost for Vaccines
Rodney Dangerfield and R&D
FindPharma Custom Search

Click here